Visit main University website

Find MND Biomarker

Find MND Biomarker

Find MND Biomarker

Find MND Biomarker

Welcome to FindMNDBiomarker, an integrative database that consolidates the proteomic findings in brain tissue and biofluids (CSF and blood) from patients with motor neuron disease (also known as amyotrophic lateral sclerosis). FightMNDBiomarker is designed for users to quickly assess whether their proteins of interest have been identified in other cohorts and biosamples from patients with MND/ALS.

Purpose: The goal of this search platform is to facilitate the comparison and discovery of proteins that may serve as promising and reproducible biofluid biomarkers of brain-specific changes in MND/ALS and to identify markers that should be further targeted for analyses and validation.

Using this database: Searches can be performed by entering the protein UniProt IDs, names and sample types into the relevant search term box using free text entry. For example, entering ‘NEFL’ will generate a list of all publications in which NEFL was identified to be significantly dysregulated.

A searchable and filterable table is provided with the following columns:

  • Name: Gene name corresponding to the UniProt ID
  • UniProt ID: UniProt accession number
  • Publication: Study Reference
  • Condition: e.g.ALS – Control, ALS Fast – ALS Slow
  • Sample Type: Sample type used (Abbreviations: SMNs, single motor neurons; AH, anterior horn; PH, posterior horn)
  • Regulation: Direction of change (upregulated or downregulated)
  • Cohorts: Cohort size used for each study
  • Average age at onset ± standard deviation/age range: Average age at onset of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average age at collection ± standard deviation/age range: Average age at collection of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average PMI (range) (hours): Average postmortem interval with range (if provided by tissue studies)

To cite this database: Further details and application of this search tool are described in our manuscript “title” that can be located with this DOI: _____

Contact: For help contact rachel.tan1@sydney.edu.au
Sort by:
Total Records Found: 2896, showing 100 per page
Biomarker NameUniProt IDPublicationConditionSample TypeRegulationCohortsAverage age at onsetAverage age at collectionAverage PMI
COX6B1 P14854 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
COX6B1 P14854 Seyfried et al. 2018 ALS – Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
COX6B1 P14854 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8
COX6A1 P12074 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8
COX5B P10606 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8
COX5B P10606 Guise et al. 2023 ALS – Control Spinal cord (SMNs) Down 3 ALS, 3 control 69.3 9.2
COX5A P20674 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8
COX5A P20674 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
COX5A P20674 Guise et al. 2023 ALS – Control Spinal cord (SMNs) Down 3 ALS, 3 control 69.3 9.2
COTL1 Q14019 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CORO2A Q92828 Oeckl et al. 2020 ALS – Control Spinal cord Down 8 ALS, 7 control 59 (52-61) 36 (24-90)
CORO1C Q9ULV4 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8
COR1C Q9ULV4 Andrés-Benito et al. 2020 ALS – Control CSF Down 15 ALS, 15 control 61 ± 10.8
COPS4 Q9BT78 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
COPS3 J3QKR0 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
COPB2 P35606 Guise et al. 2023 ALS – Control Spinal cord (SMNs) Down 3 ALS, 3 control 69.3 9.2
COMP P49747 Oeckl et al. 2020 ALS – Control Spinal cord Down 8 ALS, 7 control 59 (52-61) 36 (24-90)
COMP P49747 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
COMP P49747 Katzeff et al. 2020 ALS – Control Serum Down 28 ALS, 22 control 52.7
COMP P49747 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
COL8A1 P27658 Oeckl et al. 2020 ALS – Control CSF Up 26 ALS, 16 control
COL8A1 P27658 Oeckl et al. 2020 sALS – Control CSF Up 12 ALS, 16 control 66 (57-68) 67 (58-74)
COL8A1 P27658 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
COL6A3 P12111 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
COL6A2 P12110 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
COL5A2 P05997 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
COL4A2 P08572 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8
COL4A2 P08572 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
COL28A1 Q2UY09 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
COL21A1 Q96P44 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
COL1A1 P02452 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
COL18A1 P39060 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
COL16A1 Q07092 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
COL15A1 P39059 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
COL14A1 Q05707 Oeckl et al. 2020 ALS – Control Spinal cord Up 8 ALS, 7 control 59 (52-61) 36 (24-90)
COA3 Q9Y2R0 Seyfried et al. 2018 ALS – Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
CNTNAP5 Q8WYK1 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CNTNAP4 Q9C0A0 Zhou et al. 2023 BO-ALS – Control CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
CNTNAP3 Q9BZ76 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CNTNAP2 Q9UHC6 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
CNTNAP1 P78357 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
CNRIP1 Q96F85 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
CNPY4 Q8N129 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CNP P09543 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
CNN3 Q15417 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8
CNDP2 Q96KP4 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CNDP2 Q96KP4 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
CNDP1 Q96KN2 Zhou et al. 2023 BO-ALS – Control CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
CLVS2 Q5SYC1 Oeckl et al. 2020 ALS – Control Spinal cord Down 8 ALS, 7 control 59 (52-61) 36 (24-90)
CLVS2 Q5SYC1 Guise et al. 2023 ALS – Control Spinal cord (SMNs) Down 3 ALS, 3 control 69.3 9.2
CLUL1 Q15846 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CLU P10909 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CLTB P09497 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8
CLTA P09496 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
CLSTN1 O94985 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
CLIC4 Q9Y696 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CLIC1 O00299 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8
CLEC3B P05452 Zubiri et al. 2018 ALS fast – ALS slow (early stage) Plasma Down 8 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
CLEC2L P0C7M8 Oeckl et al. 2020 ALS – Control Spinal cord Down 8 ALS, 7 control 59 (52-61) 36 (24-90)
CLCC1 Q96S66 Andrés-Benito et al. 2020 ALS – Control CSF Down 15 ALS, 15 control 61 ± 10.8
CLC Q05315 Leoni et al. 2019 BO-ALS – LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS)
CLASP2 E7EW49 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8
CKMT2 P17540 Oeckl et al. 2020 ALS – Control Spinal cord Down 8 ALS, 7 control 59 (52-61) 36 (24-90)
CKMT2 P17540 Seyfried et al. 2018 ALS – Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
CKMT1A P12532 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8
CKM P06732 Katzeff et al. 2020 ALS – Control Serum Up 28 ALS, 22 control 52.7
CKB P12277 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
CKB P12277 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CKAP4 Q07065 Guise et al. 2023 ALS – Control Spinal cord (SMNs) Down 3 ALS, 3 control 69.3 9.2
CISD1 Q9NZ45 Seyfried et al. 2018 ALS – Control Prefrontal cortex Down 8 ALS, 8 control 60 63.5 9.1
CHST6;CHST5 Q9GZX3 Oeckl et al. 2020 sALS – Control CSF Up 12 ALS, 16 control 66 (57-68) 67 (58-74)
CHST6 Q9GZX3 Oeckl et al. 2020 ALS – Control CSF Up 26 ALS, 16 control
CHST6 Q9GZX3 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
CHST3 Q7LGC8 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CHST15 Q7LFX5 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CHST12 Q9NRB3 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CHST1 O43916 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CHRD Q9H2X0 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CHP1 Q99653 Seyfried et al. 2018 ALS – Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
CHP1 Q99653 Englen-Lee et al. 2017 ALS – Control Spinal cord (PH & AH) Up 10 ALS, 10 control 57.6 ± 10.9 62.6 ± 10.6
CHORDC1 Q9UHD1 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8
CHMP4B Q9H444 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8
CHMP4A Q9BY43 Hayashi et al. 2020 ALS – Control CSF exosome-enriched fractions Down 3 ALS, 3 control 74.3
CHMP2A O43633 Seyfried et al. 2018 ALS – Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
CHIT1 Q13231 Oeckl et al. 2020 ALS – Control CSF Up 26 ALS, 16 control
CHIT1 Q13231 Vu et al. 2023 ALS fast – ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
CHIT1 Q13231 Oeckl et al. 2020 sALS – Control CSF Up 12 ALS, 16 control 66 (57-68) 67 (58-74)
CHIT1 Q13231 Oh et al. 2023 ALS – Control CSF Up 20 ALS, 20 control 59
CHIT1 Q13231 Barschke et al. 2020 C9-ALS – C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CHIT1 Q13231 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
CHIT1 Q13231 Thompson et al. 2018 ALS – Control CSF Up 43 ALS, 25 control 59.32 ± 10.9 61.9 ± 10.3
CHI3L2 Q15782 Oeckl et al. 2020 ALS – Control CSF Up 26 ALS, 16 control
CHI3L2 Q15782 Oeckl et al. 2020 sALS – Control CSF Up 12 ALS, 16 control 66 (57-68) 67 (58-74)
CHI3L2 Q15782 Collins et al. 2015 ALS – Control CSF Up 90 ALS, 80 control
CHI3L2 Q15782-6 Bereman et al. 2018 ALS – Control CSF Up 33 ALS, 30 control
CHI3L2 Q15782 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
CHI3L2 Q15782 Barschke et al. 2020 C9-ALS – C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
CHI3L2 Q15782 Thompson et al. 2018 ALS – Control CSF Up 43 ALS, 25 control 59.32 ± 10.9 61.9 ± 10.3
CHI3L1 P36222 Oeckl et al. 2020 ALS – Control CSF Up 26 ALS, 16 control
CHI3L1 P36222 Oeckl et al. 2020 sALS – Control CSF Up 12 ALS, 16 control 66 (57-68) 67 (58-74)